Champions Oncology Company Profile (OTCMKTS:CSBR)

About Champions Oncology (OTCMKTS:CSBR)

Champions Oncology logoChampions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CSBR
  • CUSIP: N/A
  • Web: https://championsoncology.com
Capitalization:
  • Market Cap: $34.04 million
  • Outstanding Shares: 10,982,000
Average Prices:
  • 50 Day Moving Avg: $2.81
  • 200 Day Moving Avg: $2.93
  • 52 Week Range: $1.11 - $4.79
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $15.41 million
  • Price / Sales: 2.21
  • Book Value: $0.04 per share
  • Price / Book: 77.50
Profitability:
  • EBIDTA: ($6,640,000.00)
  • Net Margins: -39.52%
  • Return on Equity: -215.50%
  • Return on Assets: -72.50%
Misc:
  • Average Volume: 18,059 shs.
  • Short Ratio: 4.3
 

Frequently Asked Questions for Champions Oncology (OTCMKTS:CSBR)

What is Champions Oncology's stock symbol?

Champions Oncology trades on the OTCMKTS under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (OTCMKTS:CSBR) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $3.72 million for the quarter. Champions Oncology had a negative net margin of 39.52% and a negative return on equity of 215.50%. View Champions Oncology's Earnings History.

When will Champions Oncology make its next earnings announcement?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Thursday, September, 7th 2017. View Earnings Estimates for Champions Oncology.

Who are some of Champions Oncology's key competitors?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:

  • Joel Ackerman, Chairman of the Board
  • Ronnie Morris M.D., President, Chief Executive Officer, Director
  • David Miller CPA, Vice President - Finance
  • Philip Breitfeld, Chief Strategic and Innovation Officer, Director
  • David Sidransky M.D., Lead Independent Director
  • Daniel N. Mendelson, Independent Director
  • Abba David Poliakoff, Independent Director
  • Scott R. Tobin, Independent Director

Who owns Champions Oncology stock?

Champions Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (14.23%), Vanguard Group Inc. (0.68%), GRT Capital Partners L.L.C. (0.37%) and Spark Investment Management LLC (0.37%). Company insiders that own Champions Oncology stock include Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.

Who bought Champions Oncology stock? Who is buying Champions Oncology stock?

Champions Oncology's stock was bought by a variety of institutional investors in the last quarter, including GRT Capital Partners L.L.C.. Company insiders that have bought Champions Oncology stock in the last two years include Joel Ackerman and Ronnie Morris. View Insider Buying and Selling for Champions Oncology.

How do I buy Champions Oncology stock?

Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of Champions Oncology stock can currently be purchased for approximately $3.10.


MarketBeat Community Rating for Champions Oncology (OTCMKTS CSBR)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  15
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Champions Oncology (OTCMKTS:CSBR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Champions Oncology (OTCMKTS:CSBR)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Champions Oncology (OTCMKTS:CSBR)
Earnings by Quarter for Champions Oncology (OTCMKTS:CSBR)
Earnings History by Quarter for Champions Oncology (OTCMKTS CSBR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/7/2017N/AView Earnings Details
7/27/2017Q4 2017($0.22)$3.72 millionViewN/AView Earnings Details
3/16/2017Q3 2017($0.13)$3.57 millionViewN/AView Earnings Details
11/29/2016Q2 2017($0.05)$4.46 millionViewN/AView Earnings Details
3/15/2016Q316($0.21)$1.80 million$2.60 millionViewListenView Earnings Details
12/12/2013Q1 14($0.03)ViewN/AView Earnings Details
9/13/2013Q1($0.02)ViewN/AView Earnings Details
3/14/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Champions Oncology (OTCMKTS:CSBR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Champions Oncology (OTCMKTS:CSBR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Champions Oncology (OTCMKTS:CSBR)
Insider Trades by Quarter for Champions Oncology (OTCMKTS:CSBR)
Insider Trades by Quarter for Champions Oncology (OTCMKTS:CSBR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2016Ronnie MorrisPresidentBuy30,000$1.66$49,800.00View SEC Filing  
10/19/2016Ronnie MorrisPresidentBuy10,000$1.70$17,000.00View SEC Filing  
10/18/2016Joel AckermanCEOBuy2,000$1.70$3,400.00View SEC Filing  
10/14/2016Joel AckermanCEOBuy7,300$1.67$12,191.00View SEC Filing  
10/14/2016Ronnie MorrisPresidentBuy10,305$1.66$17,106.30View SEC Filing  
10/13/2016Ronnie MorrisPresidentBuy29,695$1.67$49,590.65View SEC Filing  
10/10/2016Ronnie MorrisPresidentBuy9,537$1.66$15,831.42View SEC Filing  
10/7/2016Joel AckermanCEOBuy8,202$1.63$13,369.26View SEC Filing  
9/23/2016Joel AckermanCEOBuy33$1.65$54.45View SEC Filing  
9/21/2016Joel AckermanCEOBuy5,000$1.66$8,300.00View SEC Filing  
9/20/2016Ronnie MorrisPresidentBuy3,000$1.58$4,740.00View SEC Filing  
3/11/2015Michael Maurice BrownMajor ShareholderBuy6,250,000$0.40$2,500,000.00View SEC Filing  
3/20/2014Daniel Newman MendelsonDirectorBuy100,000$1.08$108,000.00View SEC Filing  
3/19/2014Ronnie MorrisPresidentBuy100,000$1.07$107,000.00View SEC Filing  
1/28/2013Michael Maurice BrownMajor ShareholderBuy7,000,000$0.50$3,500,000.00View SEC Filing  
1/28/2013Ronnie MorrisPresidentBuy500,000$0.50$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Champions Oncology (OTCMKTS:CSBR)
Latest Headlines for Champions Oncology (OTCMKTS:CSBR)
Source:
DateHeadline
finance.yahoo.com logoThe Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer
finance.yahoo.com - August 15 at 6:15 PM
finance.yahoo.com logoChampions Oncology, Inc. :CSBR-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 1 at 6:15 PM
americanbankingnews.com logoChampions Oncology Inc (CSBR) Releases Quarterly Earnings Results
www.americanbankingnews.com - July 28 at 6:19 PM
finance.yahoo.com logoChampions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017
finance.yahoo.com - July 27 at 5:50 PM
finance.yahoo.com logoChampions Oncology Schedules Fourth Quarter and Fiscal Year 2017 Earnings Call
finance.yahoo.com - July 17 at 5:55 PM
americanbankingnews.com logoChampions Oncology Inc (CSBR) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - June 24 at 12:38 AM
americanbankingnews.com logoChampions Oncology (CSBR) Receiving Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 22 at 1:59 PM
americanbankingnews.com logoChampions Oncology (CSBR) Given Media Impact Score of 0.56
www.americanbankingnews.com - April 18 at 10:21 AM
finance.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Financials
finance.yahoo.com - March 23 at 4:58 PM
seekingalpha.com logoChampions Oncology (CSBR) Stock Delivers Strong Quarterly Improvement
seekingalpha.com - March 21 at 10:44 AM
biz.yahoo.com logoQ3 2017 Champions Oncology Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 17 at 4:51 PM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - March 17 at 4:51 PM
finance.yahoo.com logoChampions Oncology Reports 40% Revenue Growth
finance.yahoo.com - March 16 at 5:54 PM
finance.yahoo.com logoChampions Oncology to Announce Third Quarter Financial Results on Thursday, March 16, 2017
finance.yahoo.com - March 7 at 12:11 PM
finance.yahoo.com logoChampions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research
finance.yahoo.com - February 16 at 12:28 PM
finance.yahoo.com logoChampions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program
finance.yahoo.com - January 19 at 3:18 PM
biz.yahoo.com logoQ2 2017 Champions Oncology Inc Earnings Release - After Market Close
us.rd.yahoo.com - November 30 at 9:52 AM
us.rd.yahoo.com logoChampions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership
us.rd.yahoo.com - November 30 at 9:52 AM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr
us.rd.yahoo.com - November 30 at 9:52 AM
us.rd.yahoo.com logo4:18 pm Champions Oncology (thinly traded) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis
us.rd.yahoo.com - November 30 at 9:52 AM
finance.yahoo.com logoChampions Oncology to Announce Second Quarter Financial Results on Tuesday, November 29, 2016
finance.yahoo.com - November 23 at 12:20 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Delaware Law by Certain Officers and Directors of Champions Oncology, Inc.
finance.yahoo.com - November 15 at 4:46 PM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - November 1 at 4:35 PM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - October 14 at 4:18 PM
finance.yahoo.com logo8:25 am Champions Oncology reports Q1 results, reaffirms FY17 rev guidance
finance.yahoo.com - September 9 at 9:16 AM
finance.yahoo.com logoChampions Oncology to Announce First Quarter Financial Results on Friday, September 9, 2016
finance.yahoo.com - September 6 at 9:20 AM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - July 29 at 1:11 PM
finance.yahoo.com logoChampions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
finance.yahoo.com - July 28 at 8:00 AM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - May 18 at 5:15 PM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State
biz.yahoo.com - April 13 at 4:01 PM
feeds.benzinga.com logoChampions Oncology Names Philip Breitfeld As Director
feeds.benzinga.com - April 12 at 2:06 PM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
biz.yahoo.com - March 25 at 3:02 PM
finance.yahoo.com logoChampions Oncology Reports Results for the Third Quarter Ended January 31, 2016
finance.yahoo.com - March 15 at 8:30 AM
biz.yahoo.com logoQ3 2016 Champions Oncology Inc Earnings Release - Before Market Open
biz.yahoo.com - March 15 at 7:07 AM
finance.yahoo.com logoChampions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
finance.yahoo.com - March 11 at 9:00 AM
finance.yahoo.com logoChampions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
finance.yahoo.com - March 10 at 10:00 AM
biz.yahoo.com logoCHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - December 14 at 4:35 PM
finance.yahoo.com logoChampions Oncology Leading Paradigm Shift to Incorporation of PDX Models into Clinical Trial Strategy
finance.yahoo.com - December 14 at 4:01 PM
biz.yahoo.com logoQ2 2016 Champions Oncology Inc Earnings Release - After Market Close
biz.yahoo.com - December 14 at 7:07 AM

Social

Chart

Champions Oncology (CSBR) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff